drugset / Trial / NCT06137300

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

NCT06137300 ↗

Not yet recruiting 986 enrolled Yi Yang
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.

Timeline

Start
2024-03-15
Primary completion
2026-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Urinary Kallidinogenase Unknown 0.15 unknown —

Indications